David A. Scott
13Patents
0h-index
37Co-inventors
40Inventor score
Filing activity: Aug 26, 2016 → May 10, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11248007B2 | Inhibitors of MALT1 and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12365696B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | Human Necessities | 0 | Active |
| US12377080B2 | Allosteric EGFR inhibitors and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US11730810B2 | Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response | Emerging Cross-Sectional Technologies | 0 | Active |
| US11186574B2 | Inhibitors of EGFR and/or HER2 and methods of use | Chemistry; Metallurgy | 0 | Active |
| US12318452B2 | Degraders of WEE1 kinase | Human Necessities | 0 | Active |
| US12391671B2 | Allosteric EGFR inhibitors and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US10689366B2 | Compounds for MALT1 degredation | Chemistry; Metallurgy | 0 | Active |
| US11945816B2 | Inhibitors of EGFR and/or HER2 and methods of use | Chemistry; Metallurgy | 0 | Active |
| US10711036B2 | MALT1 inhibitors and uses thereof | Human Necessities | 0 | Active |
| US12161649B2 | Inhibitors of EGFR and methods of use thereof | Human Necessities | 0 | Active |
| US12268739B2 | Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response | Emerging Cross-Sectional Technologies | 0 | Active |
| US11673891B2 | Imidazopyrimidine compounds and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.